– Reuters
Related Posts
BioNTech And OncoC4 Present Positive Phase 1/2 Data For Antibody Candidate BNT316/ONC-392 In Hard-to-Treat NSCLC At ASCO
BioNTech SE (NASDAQ:BNTX, &ldquo, BioNTech&rdquo, )) and OncoC4, Inc. (“OncoC4”), today announced positive preliminary data from the ongoing Phase 1/2 trial with the companies’ anti-CTLA-4 antibody
RAPT Therapeutics Announces Publication Of Phase 1a/1b Clinical Trial of Zelnecirnon To Treat Atopic Dermatitis In Allergy
Positive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at four weeksFurther deepening of response
CV Sciences Inc Q1 Revenue Stagnates YoY, Here Is What You Need To Know
CV Sciences, Inc. (OTCQB: CVSI) released its financial results today for the first quarter ended March 31, 2023, revealing revenues of $4.1 million for the first quarter of 2023 compared to $4.4 million for the first quarter of 2022 and a sequential increase of 7%.